专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006106423A2 NOVEL COMPOUNDS OF AMINO SULFONYL DERIVATIVES 审中-公开
标题翻译：氨基磺酰衍生物的新化合物
公开(公告)号：WO2006106423A2
公开(公告)日：2006-10-12
申请号：PCT/IB2006000941
申请日：2006-03-29
申请人： PFIZER , CHENG HENGMIAO , CRIPPS STEPHEN JAMES , DRESS KLAUS RUPRECHT , HUANG BUWEN , NAIR SAJIV KRISHAM , WANG YONG
发明人： CHENG HENGMIAO , CRIPPS STEPHEN JAMES , DRESS KLAUS RUPRECHT , HUANG BUWEN , NAIR SAJIV KRISHAM , WANG YONG
IPC分类号： C07D213/76 , C07D213/85 , C07D401/12 , C07D487/04
CPC分类号： C07D213/76 , C07D213/85 , C07D215/38 , C07D401/04 , C07D401/12 , C07D401/14 , C07D413/12 , C07D471/04 , C07D487/04 , C07D491/10
摘要： The present invention relates to compounds with formula (I) or a pharmaceutically acceptable salt thereof: (I);wherein; T is a (4 to 10)-membered heterocyclyl and wherein R 1 , R 2 and R 3 are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of the 11-ß-hsd-1 enzyme.
摘要翻译：本发明涉及式（I）化合物或其药学上可接受的盐：（I）;其中： T是（4至10）个杂环基，其中R 1，R 2和R 3如说明书中所定义。本发明还涉及包含式（I）化合物的药物组合物和治疗由11-β-hsd-1酶调节介导的病症的方法。

2. 发明申请

WO2006106423A8 AMINO SULFONYL DERIVATIVES AS INHIBITORS OF HUMAN 11-.BETA.-HYDROSYSTEROID DEHYDROGENASE 审中-公开
标题翻译：氨基磺酰衍生物作为人11-BETA-HYDROSYSTERIDID DEHYDROGENASE的抑制剂
公开(公告)号：WO2006106423A8
公开(公告)日：2007-11-08
申请号：PCT/IB2006000941
申请日：2006-03-29
申请人： PFIZER , CHENG HENGMIAO , CRIPPS STEPHAN JAMES , DRESS KLAUS RUPRECHT , HUANG BUWEN , NAIR SAJIV KRISHNAN , WANG YONG
发明人： CHENG HENGMIAO , CRIPPS STEPHAN JAMES , DRESS KLAUS RUPRECHT , HUANG BUWEN , NAIR SAJIV KRISHNAN , WANG YONG
IPC分类号： C07D213/76 , A61K31/4427 , A61K31/444 , A61K31/4709 , A61P3/00 , C07D213/85 , C07D215/38 , C07D401/04 , C07D401/12 , C07D401/14 , C07D413/12 , C07D471/04 , C07D487/04 , C07D491/10 , C07D498/04
CPC分类号： C07D213/76 , C07D213/85 , C07D215/38 , C07D401/04 , C07D401/12 , C07D401/14 , C07D413/12 , C07D471/04 , C07D487/04 , C07D491/10
摘要： The present invention relates to compounds with Formula (I) or a pharmaceutically acceptable salt thereof: Formula (I); wherein R 1 is an optionally fused pyridine ring and R 2 and R 3 together form a heterocyclic ring. The invention also relates to pharmaceutical compositions comprising the compounds of Formula (I) and methods of treating a condition that is mediated by the modulation of the 11-ß-hsd-1 enzyme.
摘要翻译：本发明涉及式（I）化合物或其药学上可接受的盐：式（I）; 其中R 1是任选稠合的吡啶环，R 2和R 3和R 3一起形成杂环。本发明还涉及包含式（I）化合物和治疗由11-β-hsd-1酶的调节介导的病症的方法的药物组合物。

3. 发明申请

WO2005060963A8 BENZENESULFONYLAMINO-PYRIDIN-2-YL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11-BETA-HSD-1) FOR THE TREATMENT OF DIABETES AND OBESITY 审中-公开
标题翻译：作为用于治疗糖尿病和肥胖症的11-β-羟基脱氢酶脱氢酶1型（11-BETA-HSD-1）的抑制剂的苯并呋喃亚胺基吡啶-2-基衍生物及其相关化合物
公开(公告)号：WO2005060963A8
公开(公告)日：2005-12-01
申请号：PCT/IB2004004056
申请日：2004-12-06
申请人： PFIZER , EDWARDS MARTIN PAUL , JOHNSON THEODORE OTTO JR , NAIR SAJIV KRISHNAN , SIU MICHAEL , TAYLOR WENDY DIANNE , CRIPPS STEPHAN JAMES , WANG YONG , CHENG HENGMIAO , SMITH CHRISTOPHER RONALD
发明人： EDWARDS MARTIN PAUL , JOHNSON THEODORE OTTO JR , NAIR SAJIV KRISHNAN , SIU MICHAEL , TAYLOR WENDY DIANNE , CRIPPS STEPHAN JAMES , WANG YONG , CHENG HENGMIAO , SMITH CHRISTOPHER RONALD
IPC分类号： A61K31/44 , A61K31/4436 , A61K31/4545 , C07C311/36 , C07C311/37 , C07D209/08 , C07D213/02 , C07D213/76 , C07D215/38 , C07D235/06 , C07D239/42 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D417/12 , C07D471/04 , C07D487/04 , C07D491/04 , C07D513/04 , A61P3/04 , A61P3/10
CPC分类号： C07D209/08 , C07D213/76 , C07D215/38 , C07D235/06 , C07D239/42 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D417/12 , C07D471/04 , C07D487/04 , C07D491/04 , C07D513/04
摘要： The present invention relates to compounds with the formula (I), or a pharmaceutically acceptable salt thereof, wherein: R is selected from the group consisting of (C1-C6)alkyl, -(CR R )t(C3-C12)cycloalkyl, -(CR R )t(C6-C12)aryl, and -(CR R )t(4-10)-membered heterocyclyl; b and k are each independently selected from 1 and 2; j is selected from the group consisting of 0, 1, and 2; t, u, p, q, and v are each independently selected from the group consisting of 0, 1, 2, 3, 4, and 5; T is a (6-10)-membered heterocyclyl containing at least one nitrogen atom; R is selected from the group consisting of H, (C1-C6)alkyl, -(CR R )t(C3-C12)cycloalkyl, -(CR R )t(C6-C12)aryl, and -(CR R )t(4-10)-membered heterocyclyl; each R and R is independently selected from H and (C1-C6)alkyl, the carbon atoms of T, R , R , R and R may each be optionally, substituted by I to 5 R groups; R is defined in the claims; The compounds of the present invention are 11 ß-hsd-1 inhibitors, and are therefore believed to be useful in the treatment of diabetes, obesity, glaucoma, osteoporosis, cognitive disorders, immune disorders, depression, hypertension, and metabolic diseases.
摘要翻译：本发明涉及具有式（I）化合物或其药学上可接受的盐，其中：R 1选自（C 1 -C 6）烷基， - （CR 3 R 4））（C 3 -C 12）环烷基， - （CR 3 R 4）t（C 6 -C 12）芳基和 - （CR 3 R 4）t（4-10） - 杂环基; b和k各自独立地选自1和2; j选自0，1和2; t，u，p，q和v各自独立地选自0,1,2,3,4和5; T是含有至少一个氮原子的（6-10） - 杂环基; R 2选自H，（C 1 -C 6）烷基， - （CR 3 R 4）t（C 3 -C 12）环烷基， - （CR 3 R 4） t（C 6 -C 12）芳基和 - （CR 3 R 4）t（4-10） - 杂环基; 每个R 3和R 4独立地选自H和（C 1 -C 6）烷基，T，R 1，R 2，R 3和R 4的碳原子，可各自任选被I至5个R 5基团取代; R 5定义在权利要求中; 本发明的化合物是11β-hsd-1抑制剂，因此被认为可用于治疗糖尿病，肥胖，青光眼，骨质疏松症，认知障碍，免疫疾病，抑郁症，高血压和代谢疾病。

4. 发明专利

SG11201400588WA OPTICAL MEASUREMENT SYSTEM, METHOD AND SCALEPLATE THEREFOR 未知
公开(公告)号：SG11201400588WA
公开(公告)日：2014-06-27
申请号：SG11201400588W
申请日：2013-09-10
申请人： WANG YONG
发明人： WANG YONG
IPC分类号： G01B11/00 , G01C15/06 , G01D5/347

5. 发明申请

WO2007089510A3 METHODS FOR DEHYDRATION OF SUGARS 审中-公开
标题翻译：蔗糖脱水方法
公开(公告)号：WO2007089510A3
公开(公告)日：2008-01-17
申请号：PCT/US2007001945
申请日：2007-01-24
申请人： BATTELLE MEMORIAL INSTITUTE , HOLLADAY JOHNATHAN E , HU JIANLI , ZHANG XINJIE , WANG YONG
发明人： HOLLADAY JOHNATHAN E , HU JIANLI , ZHANG XINJIE , WANG YONG
IPC分类号： C07D493/04 , C07H1/00 , C07H3/10 , C08G63/672
CPC分类号： C07D493/04
摘要： The invention includes a method of dehydration of a sugar using a dehydration catalyst and a co-catalyst within a reactor. A sugar is introduced and H 2 is flowed through the reactor at a pressure of less than or equal to about 300 psig to convert at least some of the sugar into an anhydrosugar product. The invention includes a process for producing isosorbide. A starting material comprising sorbitol is flowed into a reactor. H 2 is counter flowed through the reactor. The starting material is exposed to a catalyst in the presence of a co- catalyst which comprises at least one metal. The exposing is conducted at a hydrogen pressure of less than or equal to 300 psig within the reactor and the hydrogen removes at least some of any water present during the exposing and inhibits formation of colored byproducts.
摘要翻译：本发明包括使用反应器内的脱水催化剂和助催化剂使糖脱水的方法。引入糖，并且H 2 O 2以小于或等于约300psig的压力流过反应器，以将至少一些糖转化为脱水糖产物。本发明包括制备异山梨醇的方法。将含有山梨醇的原料流入反应器。 H 2反向流过反应器。在包含至少一种金属的助催化剂的存在下，将原料暴露于催化剂。暴露在反应器内在小于或等于300psig的氢气压力下进行，并且氢去除暴露期间存在的任何水中的至少一些，并且抑制着色副产物的形成。

6. 发明申请

WO2006086733A3 PROCESS FOR PREPARING MAYTANSINOID ANTIBODY CONJUGATES 审中-公开
标题翻译：制备MAYTANSINOID抗体结合物的方法
公开(公告)号：WO2006086733A3
公开(公告)日：2007-06-07
申请号：PCT/US2006004937
申请日：2006-02-10
申请人： IMMUNOGEN INC , CHARI RAVI , ZHANG WEI , MESHULAM DEBORAH H , DAI YONG , WANG YONG , AMPHLETT GODFREY W
发明人： CHARI RAVI , ZHANG WEI , MESHULAM DEBORAH H , DAI YONG , WANG YONG , AMPHLETT GODFREY W
IPC分类号： A61K47/48
CPC分类号： C07K16/2803 , A61K47/642 , A61K47/644 , A61K47/6803 , A61K47/6849 , A61K47/6851
摘要： The invention provides a process for preparing a conjugate comprising a cell binding agent chemically coupled to a drug. The process comprises covalently attaching a linker to a cell binding agent, which then is conjugated to a drug, as well as purification and holding steps, and optionally a tangential flow filtration (TFF) step.
摘要翻译：本发明提供了制备包含与药物化学偶联的细胞结合剂的缀合物的方法。该方法包括将接头共价连接到细胞结合剂上，然后与药物缀合，以及纯化和保持步骤，以及任选的切向流过滤（TFF）步骤。

7. 发明申请

WO2006014325A3 C-MET MODULATORS AND METHOD OF USE 审中-公开
标题翻译： C-MET调制器及其使用方法
公开(公告)号：WO2006014325A3
公开(公告)日：2007-03-01
申请号：PCT/US2005023364
申请日：2005-07-01
申请人： EXELIXIS INC , BANNEN LYNNE CANNE , CHAN DIVA SZE-MING , DALRYMPLE LISA ESTHER , JAMMALAMADAKA VASU , KHOURY RICHARD GEORGE , LEAHY JAMES WILLIAM , MAC MORRISON B , MANN GRACE , MANN LARRY W , NUSS JOHN M , PARKS JASON JEVIOUS , WANG YONG , XU WEI
发明人： BANNEN LYNNE CANNE , CHAN DIVA SZE-MING , DALRYMPLE LISA ESTHER , JAMMALAMADAKA VASU , KHOURY RICHARD GEORGE , LEAHY JAMES WILLIAM , MAC MORRISON B , MANN GRACE , MANN LARRY W , NUSS JOHN M , PARKS JASON JEVIOUS , WANG YONG , XU WEI
IPC分类号： C07D471/04 , A61K31/4355 , A61K31/4365 , A61K31/437 , A61K31/519 , A61K31/52 , A61K31/522 , A61P35/00 , C07D473/06 , C07D473/16 , C07D473/18 , C07D473/22 , C07D473/24 , C07D473/30 , C07D473/34 , C07D473/38 , C07D473/40 , C07D487/04 , C07D491/04 , C07D495/04
CPC分类号： C07D487/04 , C07D209/52 , C07D471/04 , C07D473/30 , C07D473/32 , C07D493/04 , C07D493/14 , C07D493/20 , C07D498/04
摘要： The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides appropriately functionalized 5,6-fused bicyclics which inhibit, regulate and/or modulate kinase receptor, particularly c-Met, KDR, and flt-3, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.
摘要翻译：本发明提供用于调节蛋白激酶酶活性以调节细胞活性如增殖，分化，程序性细胞死亡，迁移和化学侵蚀的化合物。更具体地，本发明提供了适当的功能化的5,6融合双链体，其抑制，调节和/或调节与上述细胞活性变化相关的激酶受体，特别是c-Met，KDR和flt-3信号转导途径，含有这些化合物的组合物，以及使用它们治疗激酶依赖性疾病和病症的方法。

8. 发明申请

WO2005075606B1 FISCHER-TROPSCH SYNTHESIS USING MICROCHANNEL TECHNOLOGY AND NOVEL CATALYST AND MICROCHANNEL REACTOR 审中-公开
标题翻译：使用微通道技术和新型催化剂和微通道反应器的FISCHER-TROPSCH合成
公开(公告)号：WO2005075606B1
公开(公告)日：2005-11-17
申请号：PCT/US2004042065
申请日：2004-12-15
申请人： VELOCYS INC , WANG YONG , TONKOVICH ANNA LEE , MAZANEC TERRY , DALY FRANCIS P , VANDERWIEL DAVE , HU JIANLI , CAO CHUNSHE , KIBBY CHARLES , LI XIAOHONG , BRISCOE MICHAEL D , GANO NATHAN , CHIN YA-HUEI
发明人： WANG YONG , TONKOVICH ANNA LEE , MAZANEC TERRY , DALY FRANCIS P , VANDERWIEL DAVE , HU JIANLI , CAO CHUNSHE , KIBBY CHARLES , LI XIAOHONG , BRISCOE MICHAEL D , GANO NATHAN , CHIN YA-HUEI
IPC分类号： B01J19/00 , B01J19/24 , B01J21/04 , B01J23/75 , B01J23/889 , B01J23/89 , B01J35/10 , B01J37/02 , C10G2/00
CPC分类号： C10G2/332 , B01J19/0093 , B01J21/04 , B01J23/75 , B01J23/8896 , B01J23/8913 , B01J35/0066 , B01J35/1019 , B01J35/1038 , B01J35/1042 , B01J37/0205 , B01J2219/00783 , B01J2219/00822 , B01J2219/00824 , B01J2219/00826 , B01J2219/00831 , B01J2219/00835 , B01J2219/00844 , B01J2219/0086 , B01J2219/00873 , C10G2/341 , C10G2300/301 , C10G2300/4018 , C10G2300/4025 , C10G2300/70 , C10G2400/04 , C10G2400/10 , Y02P20/582
摘要： The disclosed invention relates to a process for converting a reactant composition comprising H2 and Co to a product comprising at least one aliphatic hydrocarbon having at least about 5 carbon atoms, the process comprising: flowing the reactant composition through a microchannel reactor in contact with a Fischer-Tropsch catalyst to convert the reactant composition to the product, the microchannel reactor comprising a plurality of process microchannels containing the catalyst; transferring heat from the process microchannels to a heat exchanger; and removing the product from the microchannel reactor; the process producing at least about 0.5 gram of aliphatic hydrocarbon having at least about 5 carbon atoms per gram of catalyst per hour; the selectivity to methane in the product being less than about 25%. The disclosed invention also relates to a supported catalyst comprising Co, and a microchannel reactor comprising at least one process microchannel and at least one adjacent heat exchange zone.
摘要翻译：所公开的发明涉及将包含H 2和Co的反应物组合物转化成包含至少一种具有至少约5个碳原子的脂族烃的产物的方法，该方法包括：使反应物组合物流过与Fischer接触的微通道反应器 - 催化剂将反应物组合物转化成产物，微通道反应器包含多个含有催化剂的工艺微通道; 将热量从工艺微通道传递到热交换器; 并从微通道反应器中除去产物; 该方法每小时产生至少约0.5克具有至少约5个碳原子的每克催化剂的脂族烃; 产品中甲烷的选择性小于约25％。所公开的发明还涉及包含Co的载体催化剂和包含至少一个工艺微通道和至少一个相邻的热交换区的微通道反应器。

9. 发明申请

WO0038117B1 METHOD AND SYSTEM FOR A VIRTUAL ASSEMBLY DESIGN ENVIRONMENT 审中-公开
标题翻译：虚拟装配设计环境的方法和系统
公开(公告)号：WO0038117B1
公开(公告)日：2000-09-21
申请号：PCT/US9930753
申请日：1999-12-23
申请人： UNIV WASHINGTON , NAT INST OF STANDARDS & TECH , JAYARAM SANKAR , JAYARAM UMA , WANG YONG , TIRUMALI HRISHIKESH , CHANDRANA HIRAL , CONNACHER HUGH , LYONS KEVIN , HART PETER
发明人： JAYARAM SANKAR , JAYARAM UMA , WANG YONG , TIRUMALI HRISHIKESH , CHANDRANA HIRAL , CONNACHER HUGH , LYONS KEVIN , HART PETER
IPC分类号： G06T19/00 , G06T17/40
CPC分类号： G06T19/20 , G06T2210/21 , G06T2219/2004 , G06T2219/2008
摘要： The invention provides a virtual assembly design environment (VAE) that can simulate axial and planar constrained motion for multiple parts in any combination and application order. Each sequence of assembly operations can be recorded and stored for later usage. A guidance mechanism may be employed by a user to assist in performing the assembly operations. Dynamic simulation methods may be used to simulate object behavior in the VAE using physical laws and collision detection algorithms. The physical properties of the parts can be created in a separate CAD system (including mass properties). In the invention, physical property information is transferred from the CAD system to a virtual reality environment where it is used in dynamic simulations. The parts behave realistically in the user's hand, constrained on the base part, or moving freely in space. A swept volume can be generated directly in the CAD system which is more accurate and compact than those created using numerical methods and can be easily processed by CAD systems. A swept volume trajectory editing mechanism has been implemented. Real time bi-directional data transfer between the VR environment and the CAD system has been achieved. The user can perform parametric design modifications in the virtual environment through a CAD system.
摘要翻译：本发明提供了一种虚拟装配设计环境（VAE），其可以以任何组合和应用顺序模拟多个部件的轴向和平面约束运动。装配操作的每个顺序都可以被记录并存储以供以后使用。用户可以使用指导机制来辅助执行组装操作。动态仿真方法可用于使用物理定律和碰撞检测算法来模拟VAE中的对象行为。零件的物理属性可以在单独的CAD系统中创建（包括质量属性）。在本发明中，物理属性信息从CAD系统转移到虚拟现实环境中，在虚拟现实环境中用于动态模拟。这些部件在用户的手中表现得真实，限制在底座部分上，或者在空间中自由移动。扫描体积可以直接在CAD系统中生成，比使用数值方法创建的更精确和更紧凑，并且可以通过CAD系统轻松处理。扫描音量轨迹编辑机制已经实施。 VR环境和CAD系统之间的实时双向数据传输已经实现。用户可以通过CAD系统在虚拟环境中执行参数化设计修改。

10. 发明申请

WO2011091307A8 AFFINITY HYDROGELS FOR CONTROLLED PROTEIN RELEASE 审中-公开
标题翻译：用于控制蛋白释放的亲和水凝胶
公开(公告)号：WO2011091307A8
公开(公告)日：2011-09-09
申请号：PCT/US2011022128
申请日：2011-01-21
申请人： UNIV CONNECTICUT , WANG YONG , SOONTORNWORAJIT BOONCHOY , CHEN NIANCAO
发明人： WANG YONG , SOONTORNWORAJIT BOONCHOY , CHEN NIANCAO
IPC分类号： A61K47/48
CPC分类号： A61K47/48784 , A61K38/27 , A61K47/48092 , A61K47/549 , A61K47/6903 , A61K47/6921
摘要： The present invention relates to novel porous matrix composites and formulations for controlled protein delivery and the uses therefor. The present invention also provides methods of synthesizing such protein delivery systems. The composites comprise affinity sites embedded in the matrix where the affinity sites are functionalized with nucleic acid aptamers having high affinity for proteins to be released. The aptamers function as binding affinity sites for the proteins to be released. In certain embodiments, release rates are controlled by tuning the binding affinity of the nucleic acid aptamerd to the proteins at a desired level. In yet other embodiments, complementary oligonucleotides that hybridize with the aptamerd are employed to trigger accelerated release of the proteins when desired. Various in situ injectable hydro gels functionalized with aptamers are provided for treating a condition and disease in a subject in need of a therapeutic protein.
摘要翻译：本发明涉及用于受控蛋白质递送的新型多孔基质复合材料和制剂及其用途。本发明还提供合成这种蛋白质递送系统的方法。复合物包含嵌入基质中的亲和位点，其中亲和位点用对待释放的蛋白质具有高亲和力的核酸适体功能化。适体作为待释放蛋白质的结合亲和位点发挥功能。在某些实施方案中，通过调节核酸适体与蛋白质的结合亲和力达到所需水平来控制释放速率。在其他实施方案中，当需要时，与适体杂交的互补寡核苷酸被用于触发蛋白的加速释放。提供了用适体官能化的各种原位可注射水凝胶，用于治疗需要治疗性蛋白质的受试者中的病症和疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式